Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

NORCROSS, Ga., March 29, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2012. These results are included in the Company's Quarterly Report on Form 10-K, which has been filed with the SEC.

"It was a year of great progress for our Company," said Peter G. Traber , M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "We completed a significant fundraising and our stock was listed on the NASDAQ Capital Market earlier in the year, we relocated our headquarters to Norcross, Georgia during the fourth quarter, and we made significant advances developing our fibrosis program. We have continued this progress into 2013, having submitted an IND for GR-MD-02 in January and received the FDA's ok that we could proceed with a Phase 1 clinical trial. We expect to initiate a Phase 1 clinical trial of GR-MD-02 during the second quarter of 2013 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and have engaged CTI Clinical Trial Services to provide services related to this trial. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic options."

At December 31, 2012, the Company had $9.4 million of non-restricted cash and cash equivalents available to fund future operations.  The Company believes that with the funds on hand at December 31, 2012, there is sufficient cash to fund core operations and planned research and development through the first quarter of 2014.

For the fourth quarter of 2012, the Company reported a net lo
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... ... three Fast Track SBIR grants from the National Institutes of Health to develop original in ... model the reaction rates of DNA and RNA experiments. , ... (Vocus) July 22, 2009 -- DNA Software, Inc. has been ...
... , PHILADELPHIA, July 22 ERT (Nasdaq: ... ePRO, and other services to the biopharmaceutical, medical device, and related ... Management, Tammy Miller. Ms. Miller will report to the Executive Vice ... Miller will be responsible for the global implementation and delivery of ...
... GOTHENBURG, Sweden, July 22 Cellectricon, a ... discovery,today announced its collaboration with University of Lodz, Poland. ... world,s first,system for high throughput transfection enabling reagent-free delivery ... To view the Multimedia News Release, please click: ...
Cached Biology Technology:DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies 2DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies 3DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies 4ERT Appoints New Vice President of Project Management 2ERT Appoints New Vice President of Project Management 3University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer 2
(Date:4/17/2014)... Professor Luca Razzari of the nergie Matriaux Tlcommunications ... from the John R. Evans Leaders Fund of ... acquisition of state-of-the-art biotech and nanophotonics equipment. To ... the Ministre de l,Enseignement suprieur, de la Recherche, ... These new laboratories will help us develop new ...
(Date:4/17/2014)... MANHATTAN, KAN. A Kansas State University engineer ... security and remotely detects improvised explosive devices. The ... , William Dunn, the Steven M. and Kay ... of mechanical and nuclear engineering, and his research ... explosives hidden underground or in car trunks. The ...
(Date:4/17/2014)... . If a ... him, he can expect his premises to be trashed. Warnings ... consequences is enough to make restaurant owners pay up. Similarly, ... eggs in other birds, nests. If the host birds throw ... by destroying the entire nest. Consequently, it is beneficial for ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... help to protect against some food allergies. Kefir, a traditional ... food, and is often used to wean babies, as it ... children under the age of three, with around 5-8% of ... the problematic food. , "Friendly" bacteria in kefir may play ...
... Small but remarkable fossils found in New Zealand will prompt a ... the so-called "land of birds" was once home to mammals as ... and a leg - belonged to a unique, mouse-sized land animal ... St Bathans fossil bed, in the Central Otago region of South ...
... Columbia University's Mailman School of Public Health, the Centers ... Research Center have discovered a key mechanism by which ... identification of an amino acid sequence in Filoviruses that ... described in the December 2006 issue of The FASEB ...
Cached Biology News:Friendly bacteria in alcoholic milkshake could fight food allergies 2Tiny bones rewrite textbooks 2Researchers discover key mechanism by which lethal viruses Ebola and Marburg cause disease 2
... for arraying proteins of interest with ... equipment. DiscoverLight Protein Array Kits allow ... cell lysate or antibody in a ... specially designed nitrocellulose membranes with a ...
... for Alkaline Phosphatase conjugates. The product ... both the enzyme and the antibody following ... product has been chemically engineered to increase ... shelf life, resistance to various shipping conditions ...
Request Info...
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Biology Products: